Pregnancy outcomes in women with immunoglobulin A nephropathy: a nationwide population-based cohort study

Simon Jarrick1,2 · Sigrid Lundberg3,4 · Olof Stephansson5,6 · Adina Symreng5 · Matteo Bottai8 · Jonas Höijer8 · Jonas F. Ludvigsson1,7,9,10

Received: 13 August 2020 / Accepted: 22 January 2021 / Published online: 8 March 2021
© The Author(s) 2021

Abstract
Background Immunoglobulin A nephropathy (IgAN) incidence peaks in childbearing age. Data on pregnancy outcomes in women with IgAN are limited.

Methods We performed a register-based cohort study in a nationwide cohort of women with biopsy-verified IgAN in Sweden, comparing 327 pregnancies in 208 women with biopsy-verified IgAN and 1060 pregnancies in a matched reference population of 622 women without IgAN, with secondary comparisons with sisters to IgAN women. Adverse pregnancy outcomes, identified by way of the Swedish Medical Birth Register, were compared through multivariable logistic regression and presented as adjusted odds ratios (aORs). Main outcome was preterm birth (< 37 weeks). Secondary outcomes were preeclampsia, small for gestational age (SGA), low 5-min Apgar score (< 7), fetal or infant loss, cesarean section, and gestational diabetes.

Results We found that IgAN was associated with an increased risk of preterm birth (13.1% vs 5.6%; aOR = 2.69; 95% confidence interval [CI] = 1.52–4.77), preeclampsia (13.8% vs 4.2%; aOR = 4.29; 95%CI = 2.42–7.62), SGA birth (16.0% vs 11.1%; aOR = 1.84; 95%CI = 1.17–2.88), and cesarean section (23.9% vs 16.2%; aOR = 1.74, 95%CI = 1.14–2.65). Absolute risks were low for intrauterine (0.6%) or neonatal (0%) death and for low 5-min Apgar score (1.5%), and did not differ from the reference population. Sibling comparisons suggested increased risks of preterm birth, preeclampsia, and SGA in IgAN, but not of cesarean section.

Conclusion We conclude that although most women with IgAN will have a favorable pregnancy outcome, they are at higher risk of preterm birth, preeclampsia and SGA. Intensified supervision during pregnancy is warranted.

Keywords IgA nephropathy · Pregnancy · Epidemiology · Glomerulonephritis · Prognosis

Abbreviations
aOR Adjusted odds ratio
CKD Chronic kidney disease
IgAN Immunoglobulin A nephropathy
BMI Body mass index

© The Author(s) 2021
Introduction

Immune globulin A nephropathy (IgAN) is the most common primary glomerulonephritis [1, 2] and a leading cause of the global burden of chronic kidney disease (CKD) [2, 3]. Incidence rates peak in (reproductive ages in) the third and fourth decades of life. Given that there is widespread agreement that CKD increases both maternal and fetal pregnancy risks [4, 5], pregnancy could be a major concern in women with IgAN. Available studies of pregnant women with IgAN have mainly focused on the effects that pregnancy might have on maternal renal function. As such, one systematic review showed no increased risk for adverse renal outcomes in predominantly early IgAN [6]. However, there is limited knowledge of IgAN impact on pregnancy outcomes. As recently reviewed by Piccoli et al. [7] an increased risk of preeclampsia, preterm birth, and low birth weight in IgAN pregnancies has been suggested. However, previous studies either lack pregnant reference individuals without IgAN [6, 8–12] or studied IgAN as part of a mixed exposure group with several renal diagnoses where only a minority of women were suffering from IgAN [13–15].

Through a national, population-based cohort of more than 4,000 patients with biopsy-proven IgAN [16, 17], we examined pregnancy outcomes in a subset of women giving birth between 1992 and 2011 compared with pregnant women from a matched reference population. Additionally, in a sibling design, we compared pregnancies in women with IgAN and pregnancies in their sisters without biopsy-verified IgAN, to account for the influence of potential intrafamilial confounding. We hypothesized that women with IgAN are at increased risk of adverse pregnancy outcomes compared to pregnant, matched reference individuals and to their pregnant sisters.

Materials and methods

Registers

The Swedish personal identity number (PIN) is a unique code assigned to every Swedish resident at birth or immigration enabling large-scale data linkages of multiple registers [18]. In this study, we linked data on biopsy-verified IgAN from Swedish pathology departments with the Swedish Medical Birth Register (MBR), the National Patient Register (NPR) and the Total Population Register (TPR).

The MBR [19] contains data on > 98% of all births in Sweden. Information, collected prospectively, includes maternal demographic data, reproductive history, and complications from the first antenatal visit (generally within 12 weeks of gestation) through delivery and the postnatal period. The register started in 1973, but in this study, we included pregnancies from January 1, 1992 until 2011 when data on smoking and body mass index (BMI, kg/m²) were consistently reported.

The NPR includes hospital stays since 1964, with national coverage since 1987. Hospital outpatient visits have been included since 2001. The register contains data on admission and discharge, main and additional diagnoses, and surgical procedures. The register has been validated and has a high diagnostic accuracy of 85–95% for most diagnoses [20].

The TPR [21] contains demographic data on all Swedish residents. This register also links first-degree relatives to all individuals born in Sweden since 1932 who were still alive in 1961.

Definition of IgAN and selection of patients and reference individuals

We defined IgAN as having a biopsy record of IgAN (1974–2011) at any of the four pathology departments in Sweden where all renal biopsy specimens are evaluated (Stockholm, Göteborg, Linköping, and Malmö/Lund). Patients were ascertained by the local IT departments that performed renal biopsies. Biopsy reports from this region were reviewed manually (for a detailed description, see Welander et al. [17]). The result-
(secondary analysis) were included in the final analyses. Sisters with biopsy-verified IgAN were excluded (Fig. 1).

**Covariates**

We obtained data on maternal year of delivery, maternal age, early pregnancy BMI, self-reported hypertension and smoking habits from the MBR. Women were asked about smoking at their first antenatal visit and classified into three categories of smoking status (0, 1–9, ≥ 10 cigarettes per day). For power reasons, however, the participants were eventually categorized into non-smokers and smokers (for definitions, see eTable S3). Data on educational level (as a proxy for socioeconomic status) were obtained from the TPR: ≤ 9 years (compulsory school), 10–12 years (upper secondary school), and ≥ 13 years (college or university). Data on pre-pregnancy diabetes mellitus and systemic inflammatory diseases were obtained from the MBR and the NPR (corresponding ICD codes are listed in eTable S1).

**Outcomes**

Outcome data were obtained from the MBR. Main outcome was preterm birth before 37 full weeks of gestation. We also studied preeclampsia, small for gestational age, cesarean section, stillbirth or neonatal death (< 28 days postnatal age), low 5-min Apgar score (< 7) and gestational diabetes mellitus as secondary outcomes. Preterm birth was subdivided into spontaneous and medically indicated prematurity. Gestational diabetes mellitus and preeclampsia were defined as the occurrence of the corresponding ICD codes (supplementary table S2s) in the MBR or NPR from the start of pregnancy until 6 weeks after estimated delivery. We defined small for gestational age (SGA) as a birth weight below the 10th percentile using the ultrasound-based sex-specific Swedish reference curve for normal fetal growth (supplementary table S3). Data on end-stage renal disease (ESRD) at pregnancy start and during follow-up were obtained from the NPR (either chronic renal dialysis or kidney transplantation; see eTable S4 for corresponding ICD codes).
Statistical analysis

Comparisons were made according to IgAN status, and matching was omitted to maximize statistical power (age, sex, and calendar period were instead controlled through statistical adjustment). All outcomes were analyzed as dichotomous variables and presented as absolute frequencies (n) and relative frequencies (%). To estimate whether IgAN was associated with an increased risk for adverse pregnancy outcomes, we used multivariable logistic regression with cluster-robust standard errors to calculate adjusted odds ratios (aORs). For fetal or infant outcomes (except stillbirth), only live deliveries were included and outcomes were analyzed per child. Maternal outcomes were analyzed per pregnancy. For gestational diabetes, we excluded women with pre-existing diabetes. The models were adjusted for calendar year of conception, maternal age, BMI, educational level, smoking status, pre-pregnancy diabetes type 1 or 2 (except in the analysis of gestational diabetes), other autoimmune diseases (eTable S1), and multiple gestation pregnancies. As a post-hoc sensitivity analysis, we also adjusted for pre-pregnancy hypertension (self-reported in the MBR), and performed a stratified analysis including only women without hypertension.

A post-hoc power analysis found that our study had an 80% power to detect a 1.44-fold increased risk of preterm birth at a significance level at 0.05.

We used Stata Statistical Software, Release 13 (College Station, TX: StataCorp, LP) for the statistical calculations. P values < 0.05 were considered statistically significant.

Ethics

The study was approved by the Stockholm Ethics Review Board (January 22, 2014; Dnr 2013/2095-31/2). Because this was a strictly register-based study, informed consent was waived by the Board [23].

Results

Background

The primary analysis compared 208 women with IgAN and 622 reference individuals. The women with IgAN gave birth to 333 children after 327 pregnancies while the reference women without IgAN gave birth to 1088 children after 1060 pregnancies. In the secondary analysis, 77 women with IgAN and 125 children from 122 pregnancies were compared with their 90 sisters giving birth to 167 children from 160 pregnancies. Demographic data are presented in Table 1. Pre-gestational diabetes was more common in women with IgAN than in reference individuals (OR = 7.77; 95%CI = 2.00–30.2), but not compared with their sisters (OR = 1.07, 95%CI = 0.28–4.07). The distribution of age at conception, educational level, BMI, smoking status, parity and any systemic inflammatory disease other than IgAN was similar in women with IgAN and those without.

Pregnancy-related outcomes

Pregnancy-related outcomes are summarized in Table 2. Women with IgAN were at increased risk of preterm birth (13.1%), compared with reference women (5.6%; aOR = 2.69, 95%CI = 1.52–4.77); this was only found for medically indicated preterm birth (aOR = 6.55, 95%CI = 3.02–14.2), whereas spontaneous prematurity was similar between groups (aOR 1.04, 95%CI = 0.46–2.34). Adjusting also for hypertension altered the aOR for preterm birth only marginally (2.42, 95%CI = 1.32–4.42), as did the exclusion of hypertensive women (aOR 2.45, 95%CI = 1.33–4.49). The rate of very preterm birth before 34 weeks GA was not significantly increased compared to population controls. Women with IgAN had more than a four-fold higher risk of preeclampsia (13.8%) compared with reference individuals (4.2%; aOR = 4.29; 95%CI = 2.42–7.62). Infants born to women with IgAN were more often SGA (16%) compared with reference infants (11.1%; aOR = 1.84; 95%CI = 1.17–2.88). The risk of cesarean section was higher in women with IgAN compared with reference individuals. Rates of stillbirth were low and did not differ between women with IgAN (0.6%) and reference individuals (0.5%). No infants born to women with IgAN died in the neonatal period, and only three (0.3%) among reference individuals and one (0.6%) among sisters did. Gestational diabetes (<1%) and fetal distress (as measured by a low 5-min Apgar score, <2%) were rare both in women with IgAN and reference individuals. Similarly, sibling comparisons, although not statistically significant, suggested increased risks of preeclampsia, SGA, and preterm delivery in pregnancies complicated by IgAN. No association was found between maternal IgAN and cesarean section.

Discussion

In this nationwide population-based cohort of more than 300 pregnancies in women with IgAN, we found an almost three-fold increased risk of preterm birth and a four-fold increased risk of preeclampsia. These findings were confirmed in sibling comparisons, although risk estimates were generally lower in these analyses, suggesting that genetic or environmental confounding factors shared within families might contribute to adverse pregnancy outcomes in women with IgAN.
Comparison with previous studies

Our study is the largest study of pregnancy-related outcomes in women with IgAN and the only study using population-based reference individuals. Most studies have been restricted to tertiary centers that could introduce selection bias, which may explain reports of perinatal mortality as high as 2–3% even in high-income countries [10, 11]. In contrast, intratuterine death was seen in only 0.6% of the pregnancies in women with IgAN in our study, and none of the offspring of IgAN mothers died < 28 days postnatal age. These findings are both important and comforting to women with IgAN in fertile age.
Strengths and limitations

The most obvious strength of our study is its large size (327 pregnancies in more than 200 women with IgAN). This resulted in a substantial statistical power to detect even small variations in risk. Moreover, we included a reference group of pregnant women who were selected from the same population as the IgAN women. This reference group allowed direct comparisons of pregnancy outcomes with adjustment for important confounders associated with adverse pregnancy outcomes (e.g., maternal age, smoking, BMI, and education). Because our study is population-based with national coverage, it should increase generalizability, at least within a high-income country context.

We used biopsy reports to ascertain IgAN. This approach has high sensitivity given that renal biopsy is mandatory for the diagnosis. Still, some patients, especially those with less severe disease, may go undetected. Biopsy reports for IgAN also have high specificity, as shown in our recent patient chart review. Of the 127 randomly selected patients, 121 had a clinical diagnosis of IgAN, corresponding to a positive predictive value of 95%. IgA deposits were reported in 97% of the biopsies and C3 deposits were seen in 89% of the patients [16]. Moreover, the MBR has a high coverage rate with only 0.5–5.0% missing records. For instance, more than 95% of pregnant Swedish women undergo early second trimester ultrasound to enable calculations of gestational age [19]. Finally, the TPR permitted the identification of pregnancies in sisters of women with IgAN. Pregnancy outcomes are influenced by a number of factors, some of which are subtle and not recorded in routine health care data or even possible to measure (e.g., health awareness and physical activity). Through our sibling comparisons, we could minimize the impact of intrafamilial confounding, and importantly, the positive association with adverse pregnancy outcome persisted for preeclampsia and SGA, albeit failing to reach statistical significance because of limited statistical power to detect population differences. The somewhat lower risk estimates in sibling comparisons may also signal the presence of residual confounding and shared

### Table 2

Maternal and infant outcomes in pregnant women with IgAN compared to general population controls and to their sisters

|                     | IgAN n (%) | Reference n (%) | aOR (95%CI) | IgAN n (%) | Sisters n (%) | aOR (95%CI) |
|---------------------|------------|-----------------|-------------|------------|---------------|-------------|
| Women               |            |                 |             |            |               |             |
| Pregnancies         | 208 (62)   | 327 (106)       |             | 116 (15)   | 122 (160)     |             |
| Births (stillbirth) | 333 (2)    | 1,088 (5)       |             | 125 (1)    | 167 (0)       |             |
| Pregnancies, n      | 327        | 1,060           |             | 120        | 162           |             |
| Preterm birth <37 w<sup>a</sup> | 43 (13.1%) | 59 (5.6%)       | 2.69 (1.52-4.77) | 7 (5.7%)   | 5 (3.1%)      | 1.37 (0.24-7.73) |
| Medically indicated<sup>d</sup> | 29 (8.9%)  | 18 (1.7%)       | 6.55 (3.02-14.2) | 6 (4.9%)   | 2 (1.3%)      | 2.74 (0.22-34.97) |
| Spontaneous<sup>a</sup> | 14 (4.3%)  | 41 (3.9%)       | 1.04 (0.46-2.34) | 1 (0.8%)   | 3 (1.9%)      | 0.32 (0.01-19.47) |
| Very preterm <34 w<sup>a</sup> | 7 (2.1%)   | 18 (1.7%)       | 1.27 (0.52-5.34) |             |               |             |
| Preeclampsia<sup>a</sup> | 45 (13.8%) | 44 (4.2%)       | 4.29 (2.42-7.62) | 11 (9%)    | 9 (5.6%)      | 2.46 (0.49-12.43) |
| Gestational diabetes<sup>b</sup> | 3 (0.9%)   | 2 (0.2%)        | 6.97 (1.21-40.21) | 0 (0%)     | 2 (1.3%)      | i           |
| Live births, n      | 331        | 1,083           |             | 124        | 167           |             |
| Neonatal death<sup>b</sup> | 0 (0%)     | 3 (0.3%)        |             | 0 (0%)     | 1 (0.6%)      |             |
| Small for gestational age<sup>c</sup> | 53 (16.0%) | 120 (11.1%)    | 1.84 (1.17-2.88) | 21 (16.9%) | 19 (11.4%)    | 1.73 (0.84-3.58) |
| Apgar <7 at 5 min    | 6 (1.8%)   | 15 (1.4%)       | 1.56 (0.5-4.81) | 1 (0.8%)   | 3 (1.8%)      | 0.50 (0.03-8.92) |
| Cesarean section     | 79 (23.9%) | 175 (16.2%)     | 1.74 (1.14-2.65) | 24 (19.4%) | 36 (21.6%)    | 0.74 (0.35-1.59) |
| Birth weight (g), mean (SD) | 3,337 (693) | 3,520 (596)   | P<0.0001<sup>i</sup> |             |               |             |

<sup>a</sup>Odds ratios adjusted for year of delivery, maternal age, body mass index (BMI), educational level, smoking (yes/no), pre-pregnancy diabetes (ICD9: 250, ICD10: E10-E11), other systemic inflammatory diseases (ICD codes in eTable S2), and multiple gestation pregnancies

<sup>b</sup>Infant death within 27 days postnatal age

<sup>c</sup>Birth weight below the 10th percentile for gestational week

<sup>d</sup>ICD9: 642E-H or ICD10: O14-O15 in the MBR or the NPR from pregnancy start to 6 weeks after estimated delivery

<sup>e</sup>Duration of pregnancy <37 full weeks (<258 days) in the MBR

<sup>f</sup>Code in the MBR for induction or cesarean section without the code for premature rupture of membranes

<sup>g</sup>All preterm deliveries not defined as induced

<sup>h</sup>ICD9: 648A or ICD10: O244 in the MBR or the NPR from pregnancy start to 6 weeks after estimated delivery. Women with pre-pregnancy diabetes mellitus (ICD9: 250 or ICD10: E10-E14) were excluded from the analysis

<sup>i</sup>Pre-pregnancy diabetes was not adjusted for because women with this diagnosis were excluded from these analyses

<sup>j</sup>Model not possible to estimate

<sup>k</sup>Duration of pregnancy < 34 full weeks (<230 days) in the MBR

<sup>l</sup>Unpaired t-test
risk factors, and that some part of the risk increase in IgAN women might be due to genetic or environmental risk factors shared with their sisters without IgAN.

Our study has some limitations. First, because our database does not include data on glomerular function or proteinuria, we could not stratify for IgAN disease activity or severity. Previous studies have suggested a correlation between adverse pregnancy outcomes (e.g., preeclampsia, preterm birth, low birth weight, and SGA) and impaired glomerular function [24]. Second, we were unable to stratify our patients according to underlying cause for consultation. In our patient chart review, macroscopic hematuria (29%) and urinary screening (26%) were the two most common reasons for IgAN work-up [16].

**Mechanisms**

Glomerular diseases, including IgAN, are associated with high rates of hypertension and proteinuria. Not surprisingly, IgAN patients are at increased risk for vascular disease [25]. As such, IgAN during pregnancy shares characteristics with preeclampsia, which may be difficult to distinguish from features of the primary glomerular disease [26]. IgAN appears to bear a particularly high risk of preeclampsia [14], as witnessed by the more than four-fold increased risk in our cohort. Because preeclampsia is a main risk factor for adverse pregnancy outcomes, including preterm birth and intrauterine growth restriction, a similar pattern could be expected in IgAN. Previous studies have indeed indicated elevated risks of preterm birth and intrauterine growth restriction or SGA in CKD, increasing with CKD stage and with hypertension and high-grade proteinuria in CKD stage 1 [14, 15, 27]. Still, a sub-classification of preeclampsia has been suggested into an early (<34 weeks of gestation) “placental” phenotype, depending on a primary abnormal placentaion and the subsequent release into the bloodstream of vasoactive substances, and a late (>34 weeks) “maternal” phenotype in which pre-existing endothelial dysfunction in women with hypertensive disease interacts with a primarily normal placenta. The placental phenotypes have been associated with much higher risks of adverse pregnancy outcomes, including a two-fold increased risk of SGA [28, 29].

The maternal phenotype could be expected to dominate in women with IgAN, who carry a high risk of hypertension, proteinuria, and vascular dysfunction before pregnancy [25]. This view is supported by a recent meta-analysis, comparing pregnancy in IgAN with pregnancy in a low-risk reference population, demonstrating a low SGA frequency (10.4%, non-significant OR = 1.27) in IgAN women despite a very high presence of preeclampsia (15.1%, OR = 11.80) [24]. In contrast, our IgAN cohort, with slightly less preeclampsia (13.8%), had a high and significantly increased occurrence of SGA (16.0%, aOR = 1.83). The observed increase of SGA is even more pronounced than what could be expected solely from preeclampsia, indicating that there may be other pathways linking IgAN and SGA. A diagnosis of early “placental” preeclampsia also may be missed to some extent in IgAN due to already present proteinuria and hypertension, which are expected to increase after cessation of blockers of the renin angiotensin system due to the pregnancy.

We found a pronounced increase in medically indicated preterm births, whereas the rate of spontaneous preterm birth was similar between groups. Although we did not examine each case separately, this increase could probably be explained by high rates of preeclampsia and SGA among women with IgAN, as these are common causes for medically indicated labor before term gestation.

**Conclusion**

Our findings suggest that although most women with IgAN will have a favorable pregnancy outcome, IgAN in pregnancy may be linked to preeclampsia, preterm birth, and SGA. Our data support extra counseling and supervision of pregnant women with IgAN.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s40620-021-00979-2.

**Author contributions** SJ and JFL conceived and designed the study with input from the other authors. SJ and JFL wrote the first draft of the paper. JFL supervised the project. JFL obtained funding for data collection and register-based linkages. JH and MB analyzed the data. All authors interpreted the data and contributed to the writing of the paper. All authors revised and approved the final version. JFL had full access to all the data and takes responsibility for the integrity of the data. JH and MB take responsibility for the accuracy of the data analyses.

**Funding** Open access funding provided by Karolinska Institute. This study was supported by grants from the Research Committee of Örebro County Council. Dr. Ludvigsson coordinates a study unrelated to the present study on behalf of the Swedish IBD quality register (SWIBREG). That study has received funding from Janssen corporation.

**Data sharing** Other researchers can be granted individual access to our data through the Swedish National Board of Health and Welfare.

**Compliance with ethical standards**

**Conflict of interest** All authors have completed the Unified Competing Interest form (available on request from the corresponding author) and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; and no other relationships or activities that could appear to have influenced the submitted work.

**Ethical approval** This project (2013/2095-31/2) was approved by the Ethics Review Board in Stockholm, Sweden on January 22, 2014.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Simon P, Ramee M-P, Boulahrouz R et al (2004) Epidemiologic data of primary glomerular diseases in western France. Kidney Int 66(3):905–908
2. McGrogan A, Franssen CF, de Vries CS (2011) The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant 26(2):414–430
3. Pesce F, Schena FP (2010) Worldwide distribution of glomerular diseases: the role of renal biopsy registries. Nephrol Dial Transplant 25(2):334–336
4. Nevis IF, Reitsma A, Dominic A et al (2011) Pregnancy outcomes in women with chronic kidney disease: a systematic review. Clin J Am Soc Nephrol 6(11):2587–2598
5. Piccoli GB, Attini R, Vasario E et al (2010) Pregnancy and chronic kidney disease: a challenge in all CKD stages. Clin J Am Soc Nephrol 5(5):844–855
6. Liu Y, Ma X, Zheng J et al (2016) A systematic review and meta-analysis of kidney and pregnancy outcomes in IgA nephropathy. Am J Nephrol 44(3):187–193
7. Piccoli GB, Kooij IA, Attini R et al (2018) A systematic review on materno-fetal outcomes in pregnant women with IgA nephropathy: a case of “late-maternal” preeclampsia? J Clin Med 7(8):212. https://doi.org/10.3390/jcm7080212
8. Su X, Lv J, Liu Y et al (2017) Pregnancy and kidney outcomes in patients with IgA nephropathy: a cohort study. Am J Kidney Dis 70(2):262–269
9. Waness A, Al Sayyari A, Salih SB et al (2010) Increased risk of hypertension, proteinuria and preeclampsia in pregnant saudi females with IgA nephropathy. Hypertens Pregnancy 29(4):385–389
10. Limardo M, Imbasciati E, Ravani P et al (2010) Pregnancy and progression of IgA nephropathy: results of an Italian multicenter study. Am J Kidney Dis 56(3):506–512
11. Liu Y, Ma X, Lv J et al (2014) Risk factors for pregnancy outcomes in patients with IgA nephropathy: a matched cohort study. Am J Kidney Dis 64(5):730–736
12. Abe S (1994) The influence of pregnancy on the long-term renal prognosis of IgA nephropathy. Clin Nephrol 41(2):61–64
13. O’Shaughnessy MM, Jobson MA, Sims K et al (2017) Pregnancy outcomes in patients with glomerular disease attending a single academic center in North Carolina. Am J Nephrol 45(5):442–451
14. Piccoli GB, Attini R, Cabiddu G et al (2017) Maternal-fetal outcomes in pregnant women with glomerulonephritides. Are all glomerulonephritides alike in pregnancy? J Autoimmun 79:91–98
15. Li Y, Wang W, Wang Y et al (2018) Fetal risks and maternal renal complications in pregnancy with preexisting chronic glomerulonephritis. Med Sci Monit 24:1008–1016
16. Jarrick S, Lundberg S, Welander A et al (2017) Clinical validation of immunoglobulin A nephropathy diagnosis in Swedish biopsy registers. Clin Epidemiol 9:67–73
17. Welander A, Sundelin B, Fored M et al (2013) Increased risk of IgA nephropathy among individuals with celiac disease. J Clin Gastroenterol 47:678–683
18. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU et al (2009) The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 24(11):659–667
19. Källen B, Källén K, Otterblad Olausson P (2003) The Swedish Medical Birth Register: a summary of content and quality. https://www.socialstyrelsen.se/globalassets/sharepoint-dokument/artikelkatalog/ovrigt/2003-112-3_20031123.pdf. Accessed 14 Oct 2019
20. Ludvigsson JF, Andersson E, Ekborn A et al (2011) External review and validation of the Swedish national inpatient register. BMC Public Health 11:450
21. Ludvigsson JF, Almqvist C, Bonamy AK et al (2016) Registers of the Swedish total population and their use in medical research. Eur J Epidemiol 31(2):125–136
22. SNOMED CT. https://browser.ihstdotools.org/index-ie.html?perspective=full&conceptId1=404684003&edition=se-edition&release=v20190531&server=https://prod-browser-exten.ihstdotools.org/api/snomed&langReset=46011000052107. Accessed 31 May 2019
23. Ludvigsson JF, Haberg SE, Knudsen GP et al (2015) Ethical aspects of registry-based research in the Nordic countries. Clin Epidemiol 7:491–508
24. Park S, Yoo KD, Park JS et al (2018) Pregnancy in women with immunoglobulin A nephropathy: are obstetrical complications associated with renal prognosis? Nephrol Dial Transplant 33(3):459–465
25. Myllymaki J, Syrjanen J, Helin H et al (2006) Vascular diseases and their risk factors in IgA nephropathy. Nephrol Dial Transplant 21(7):1876–1882
26. Piccoli GB, Cabiddu G, Castellino S et al (2017) A best practice position statement on the role of the nephrologist in the prevention and follow-up of preeclampsia: the Italian study group on kidney and pregnancy. J Nephrol 30(3):307–317
27. Zhang JJ, Ma XX, Hao L et al (2015) A systematic review and meta-analysis of outcomes of pregnancy in CKD and CKD outcomes in pregnancy. Clin J Am Soc Nephrol 10(11):1964–1978
28. Phipps E, Prasanna D, Brima W et al (2016) Preeclampsia: updates in pathogenesis, definitions, and guidelines. Clin J Am Soc Nephrol 11(6):1102–1113
29. Li X, Zhang W, Lin J et al (2018) Preterm birth, low birthweight, and small for gestational age among women with preeclampsia: Does maternal age matter? Pregnancy Hypertens 13:260–266

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.